Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908995 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects
A Phase 1 study of Healthy Adults, sponsored by EicOsis Human Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04908995: Completed Phase 1 study of Healthy Adults, sponsored by EicOsis Human Health.
NCT04908995 is a Phase 1 study of Healthy Adults that has completed, run by EicOsis Human Health. The registered enrollment target is 18 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04908995, a Phase 1 study of Healthy Adults, has completed, sponsored by EicOsis Human Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.
Primary Outcome
All AEs reported or observed during the study will be recorded on the electronic case report forms (eCRF). Information to be collected includes drug treatment, type of event, time of onset, dosage, investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome. Any AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progre
Conditions Studied
Interventions
- DRUG EC5026 oral tablet
- OTHER Placebo oral tablet
Study Locations (1)
Texas
- PPD Phase I Clinic - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 1 |
What the finished NCT04908995 record still lists
NCT04908995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which EC5026 oral tablet is the first listed.
NCT04908995 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04908995 about?
NCT04908995 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects". The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.
What is the current status of trial NCT04908995?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-04-30. Estimated completion is 2021-11-24.
What conditions does trial NCT04908995 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT04908995?
The interventions under investigation include: EC5026 oral tablet (DRUG), Placebo oral tablet (OTHER).
Who is sponsoring clinical trial NCT04908995?
This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04908995 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04908995's enrollment target sits among peer trials
18 31st of 33 higher than 3 of 33 other Healthy Adults trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI